304 related articles for article (PubMed ID: 22426410)
1. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management.
Ferrero A; Strada I; Di Marcoberardino B; Maccarini LR; Pozzati F; Rossi M; Biglia N; De Iaco P
Int J Gynecol Cancer; 2012 Sep; 22(7):1158-62. PubMed ID: 22801031
[TBL] [Abstract][Full Text] [Related]
3. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
Lorusso D; Ratti M; Ditto A; Raspagliesi F
Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
[TBL] [Abstract][Full Text] [Related]
5. New Pointers for Surgical Staging of Borderline Ovarian Tumors.
Bendifallah S; Nikpayam M; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
Ann Surg Oncol; 2016 Feb; 23(2):443-9. PubMed ID: 26442919
[TBL] [Abstract][Full Text] [Related]
6. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
8. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
9. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
10. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
11. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
Sun L; Song Y; Li N; Yuan GW; Sun YC; Li N; Ma SK; Zhang X; Wu LY
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):589-594. PubMed ID: 28835081
[No Abstract] [Full Text] [Related]
12. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
13. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
[TBL] [Abstract][Full Text] [Related]
14. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
15. Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor.
Romeo M; Pons F; Barretina P; Radua J
World J Surg Oncol; 2013 Jan; 11():13. PubMed ID: 23343188
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
17. Endocervical-like versus intestinal-type mucinous borderline ovarian tumors: a large retrospective series focusing on the clinicopathologic characteristics.
Song T; Choi CH; Lee YY; Kim TJ; Lee JW; Sung CO; Song SY; Bae DS; Kim BG
Gynecol Obstet Invest; 2013; 76(4):241-7. PubMed ID: 24192519
[TBL] [Abstract][Full Text] [Related]
18. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
[TBL] [Abstract][Full Text] [Related]
20. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
